Bicara Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend
Bicara Therapeutics Inc. (BCAX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend · last filed 2026-08-11
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average expected dividend for the quarter ending 2026-06-30 was $0.00.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average expected dividend for the quarter ending 2026-03-31 was $0.00.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average expected dividend for the quarter ending 2025-09-30 was $0.00.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average expected dividend for the quarter ending 2025-06-30 was $0.00.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average expected dividend for fiscal 2025 was $0.00.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average expected dividend for fiscal 2024 was $0.00.
- Bicara Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average expected dividend for fiscal 2023 was $0.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $0.00 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |